These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 16376743

  • 21. Rheumatoid arthritis associated with the use of Sandostatin® LAR® depot in a patient with pancreatic neuroendocrine tumor. An association or a coincidence? The first case report.
    Saif MW.
    JOP; 2011 Jul 08; 12(4):425-8. PubMed ID: 21737909
    [Abstract] [Full Text] [Related]

  • 22. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
    Spahr L, Giostra E, Frossard JL, Morard I, Mentha G, Hadengue A.
    Am J Gastroenterol; 2007 Jul 08; 102(7):1397-405. PubMed ID: 17488248
    [Abstract] [Full Text] [Related]

  • 23. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
    Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, De Caro ML, Lombardi G, De Rosa G, Colao A.
    Clin Endocrinol (Oxf); 2008 Nov 08; 69(5):756-62. PubMed ID: 18485119
    [Abstract] [Full Text] [Related]

  • 24. A pilot study of Octreotide LAR vs. octreotide tid for pain and quality of life in chronic pancreatitis.
    Lieb JG, Shuster JJ, Theriaque D, Curington C, Cintrón M, Toskes PP.
    JOP; 2009 Sep 04; 10(5):518-22. PubMed ID: 19734628
    [Abstract] [Full Text] [Related]

  • 25. Management of treatment-related intermittent partial small bowel obstruction: the use of octreotide.
    Myers J, Tamber A, Farhadian M.
    J Pain Symptom Manage; 2010 Apr 04; 39(4):e1-3. PubMed ID: 20153136
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Octreotide therapy in dumping syndrome: Analysis of long-term results.
    Didden P, Penning C, Masclee AA.
    Aliment Pharmacol Ther; 2006 Nov 01; 24(9):1367-75. PubMed ID: 17059518
    [Abstract] [Full Text] [Related]

  • 29. [Application of sandostatin in malignant bowel obstruction].
    Li J, Jing ML, Shen L.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Sep 01; 10(5):479-81. PubMed ID: 17851794
    [Abstract] [Full Text] [Related]

  • 30. Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer.
    Jong P, Sturgeon J, Jamieson CG.
    Can J Surg; 1995 Oct 01; 38(5):454-7. PubMed ID: 7553472
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
    Mystakidou K, Tsilika E, Kalaidopoulou O, Chondros K, Georgaki S, Papadimitriou L.
    Anticancer Res; 2002 Oct 01; 22(2B):1187-92. PubMed ID: 12168923
    [Abstract] [Full Text] [Related]

  • 33. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
    Watanabe H, Inoue Y, Uchida K, Okugawa Y, Hiro J, Ojima E, Kobayashi M, Miki C, Kusunoki M.
    J Pediatr Surg; 2007 Jan 01; 42(1):259-60. PubMed ID: 17208578
    [Abstract] [Full Text] [Related]

  • 34. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.
    Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, Eckermann S, Abernethy AP, Clark K.
    J Pain Symptom Manage; 2015 May 01; 49(5):814-21. PubMed ID: 25462210
    [Abstract] [Full Text] [Related]

  • 35. Continuous subcutaneous octreotide in gastrointestinal cancer patients: pain control and beta-endorphin levels.
    Befon S, Mystakidou K, Lyra M, Tubanakis N, Vlahos L.
    Anticancer Res; 2000 May 01; 20(5C):4039-46. PubMed ID: 11268498
    [Abstract] [Full Text] [Related]

  • 36. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
    Peng X, Wang P, Li S, Zhang G, Hu S.
    World J Surg Oncol; 2015 Feb 15; 13():50. PubMed ID: 25889313
    [Abstract] [Full Text] [Related]

  • 37. Randomised clinical trial investigating the effects of combined administration of octreotide and methylglucamine diatrizoate in the older persons with adhesive small bowel obstruction.
    Zhang Y, Gao Y, Ma Q, Dang C, Wei W, De Antoni F, Rocci R, Chen W.
    Dig Liver Dis; 2006 Mar 15; 38(3):188-94. PubMed ID: 16311083
    [Abstract] [Full Text] [Related]

  • 38. Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia.
    Scaglione G, Pietrini L, Russo F, Franco MR, Sorrentini I.
    Aliment Pharmacol Ther; 2007 Sep 15; 26(6):935-42. PubMed ID: 17767478
    [Abstract] [Full Text] [Related]

  • 39. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.
    Rosenoff SH, Gabrail NY, Conklin R, Hohneker JA, Berg WJ, Warsi G, Maloney J, Benedetto JJ, Miles EA, Zhu W, Anthony L.
    J Support Oncol; 2006 Jun 15; 4(6):289-94. PubMed ID: 16805331
    [Abstract] [Full Text] [Related]

  • 40. [Benefit of palliative surgery for bowel obstruction in recurrent ovarian carcinoma].
    Li ZT, Wu XH, Fu SL.
    Zhonghua Fu Chan Ke Za Zhi; 2004 Apr 15; 39(4):260-3. PubMed ID: 15130355
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.